Early detection of SARS-CoV-2 from staging PET-CT.

Journal of radiation oncology Pub Date : 2020-01-01 Epub Date: 2020-09-29 DOI:10.1007/s13566-020-00436-w
Mohamed H Khattab, Alexander D Sherry, Aaron C Jessop, Kristen K Ciombor, Bapsi Chakravarthy
{"title":"Early detection of SARS-CoV-2 from staging PET-CT.","authors":"Mohamed H Khattab,&nbsp;Alexander D Sherry,&nbsp;Aaron C Jessop,&nbsp;Kristen K Ciombor,&nbsp;Bapsi Chakravarthy","doi":"10.1007/s13566-020-00436-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>SARS-CoV-2 infection may manifest with minimal or no clinical symptoms. However, signs of infection may appear on routine imaging obtained in the care of patients with cancer. The management of patients planned for chemoradiation with asymptomatic or mildly symptomatic SARS-CoV-2 infection is uncertain.</p><p><strong>Methods: </strong>Here, we present a case study of a mildly symptomatic patient with anal cancer diagnosed with SARS-CoV-2 from a staging PET-CT scan.</p><p><strong>Results: </strong>PET-CT scan for anal cancer staging demonstrated pulmonary avidity suspicious for an infectious, rather than malignant, process. In the setting of these imaging findings and new-onset anosmia, viral polymerase chain reaction was ordered and found to be positive for SARS-CoV-2. To avoid myelosuppression in the setting of active infection, planned chemoradiation was delayed until cessation of viral shedding.</p><p><strong>Conclusion: </strong>In the COVID-19 era, oncologists obtaining routine staging imaging should have high diagnostic suspicion for subclinical SARS-CoV-2 infection. To avoid precipitating severe pneumonia and hospitalization, multidisciplinary discussion with risk-benefit analysis is recommended before initiating immunosuppressive therapies such as chemoradiation.</p>","PeriodicalId":89815,"journal":{"name":"Journal of radiation oncology","volume":"9 3-4","pages":"93-95"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13566-020-00436-w","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of radiation oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13566-020-00436-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/9/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: SARS-CoV-2 infection may manifest with minimal or no clinical symptoms. However, signs of infection may appear on routine imaging obtained in the care of patients with cancer. The management of patients planned for chemoradiation with asymptomatic or mildly symptomatic SARS-CoV-2 infection is uncertain.

Methods: Here, we present a case study of a mildly symptomatic patient with anal cancer diagnosed with SARS-CoV-2 from a staging PET-CT scan.

Results: PET-CT scan for anal cancer staging demonstrated pulmonary avidity suspicious for an infectious, rather than malignant, process. In the setting of these imaging findings and new-onset anosmia, viral polymerase chain reaction was ordered and found to be positive for SARS-CoV-2. To avoid myelosuppression in the setting of active infection, planned chemoradiation was delayed until cessation of viral shedding.

Conclusion: In the COVID-19 era, oncologists obtaining routine staging imaging should have high diagnostic suspicion for subclinical SARS-CoV-2 infection. To avoid precipitating severe pneumonia and hospitalization, multidisciplinary discussion with risk-benefit analysis is recommended before initiating immunosuppressive therapies such as chemoradiation.

Abstract Image

从分期PET-CT早期发现SARS-CoV-2。
目的:SARS-CoV-2感染可能表现为轻微或无临床症状。然而,感染的迹象可能出现在癌症患者护理中获得的常规影像学检查中。无症状或轻度症状SARS-CoV-2感染的计划放化疗患者的管理尚不确定。方法:在这里,我们报告了一例轻度症状的肛门癌患者,通过分期PET-CT扫描诊断为SARS-CoV-2。结果:PET-CT扫描肛门癌分期显示肺贪婪可疑的感染性,而不是恶性,过程。在这些影像学发现和新发嗅觉缺失的背景下,责令进行病毒聚合酶链反应,并发现SARS-CoV-2阳性。为了避免活动性感染的骨髓抑制,计划的放化疗被推迟到病毒脱落停止。结论:在COVID-19时代,肿瘤学家对亚临床SARS-CoV-2感染应持高度的诊断怀疑态度。为了避免急性肺炎和住院治疗,建议在开始免疫抑制治疗(如放化疗)之前进行多学科讨论和风险-收益分析。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书